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Abstract
Background Discrepancies in the clinicopathologic
parameters pre- and post-endoscopic submucosal dissec-
tion (ESD) sometimes necessitate additional surgical
resection. The aim of this study was to assess such dis-
crepancies in clinicopathologic parameters before and after
ESD in the context of reducing the risk of failure of
curative ESD.
Methods Data on 712 early gastric cancer patients were
prospectively collected from 12 university hospitals
nationwide. The inclusion criteria were differentiated
carcinoma \3 cm in size, no ulceration, submucosal
invasion \500 lm, and no metastasis. Clinicopathologic
factors were compared retrospectively.
Results The discrepancy rate was 20.1 % (148/737) and
the most common cause of discrepancy was tumor size (64
cases, 8.7 %). Ulceration, undifferentiated histology, and
SM2 invasion were found in 34 (4.6 %), 18 (2.4 %), and 51
cases (6.9 %), respectively. Lymphovascular invasion
(LVI) was observed in 34 cases (4.6 %). Cases with lesions
exceeding 3 cm in size showed more frequent submucosal
invasion, an elevated gross morphology, and upper and
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middle locations (p\ 0.05). In the cases with ulceration,
depth of invasion (DOI) was deeper than in the cases
without ulceration (p = 0.005). Differentiation was corre-
lated with DOI and LVI (p = 0.021 and 0.007). DOI was
correlated with tumor size, ulceration, differentiation, LVI,
gross type, and location. There were statistically significant
differences between mucosal cancer cases and submucosal
cancer cases in tumor size, differentiation, ulceration, LVI,
and location.
Conclusions The overall discrepancy rate was 20.1 %. To
reduce this rate, it is necessary to evaluate the DOI very
cautiously, because it is correlated with other parameters.
In particular, careful checking for SM-invasive cancer is
required due to the high incidence of LVI irrespective of
the depth of submucosal invasion.
Keywords Endoscopic submucosal dissection  Early
gastric cancer  Indication  Preoperative diagnosis 
Discrepancy
Introduction
Endoscopic mucosal resection/endoscopic submucosal
dissection (EMR/ESD) is accepted as a curative treatment
modality for early gastric cancer (EGC) to improve the
quality of life of patients [1]. However, the application of
ESD should be limited—it should be assigned based on
strict inclusion criteria—because of the risk of metastasis.
There is still debate regarding the indications for ESD.
Current definitive indications for endoscopic resection
include differentiated cancer limited to the mucosa, a
polypoid lesion \2 cm in size, and an excavated type
\1 cm in size without concurrent ulceration [2]. Due to the
advances made in ESD, Gotoda et al. [3] expanded the
criteria for ESD to include differentiated mucosal cancers
without ulcers regardless of lesion size, differentiated
mucosal cancers with ulcers B3 cm in size, undifferenti-
ated mucosal cancers B2 cm in size, and differentiated
submucosal cancers B3 cm in size and B500 lm (SM1) in
depth without lymphatic or vascular invasion. To fulfill
these criteria, close examinations must be performed prior
to the procedures, such as measurements of invasion depth
and tumor size as well as evaluations of differentiation and
ulceration via endoscopy, ultrasonography, and endoscopic
biopsy. Even after meticulous inspection, discrepancies
between pre- and post-ESD clinicopathologic parameters
can occur, which can necessitate additional curative surg-
eries in cases presenting deviations from the appropriate
parameter ranges. In the work reported in the present paper,
the frequency and causes of such discrepancies between
pre- and post-ESD parameters were examined with a view
to reducing the risk of failure of curative ESD.
Patients and methods
Collection of ESD specimens
The study was conducted with approval from the Institu-
tional Review Board of The National Evidence-based
Healthcare Collaborating Agency (NECA). This study
involved 12 organizations across the country that have
actively implemented ESD (NECA–Korea ESD for Early
Gastric Cancer Prospective Study: the N-Keep Study). In
each organization, ESD was performed by experienced
endoscopists.
From June 2010 to May 2011, each organization per-
formed ESD for adenomas or for EGCs that met all of the
following criteria: (1) age 20 years or older, (2) lesion
B3 cm in length based on endoscopic findings, (3) well or
moderately differentiated carcinoma based on histologic
examination of endoscopic biopsy tissue, (4) absence of
ulceration in the lesion, (5) depth of submucosal invasion
B500 lm, and (6) no metastasis based on abdominal
computed tomography (CT) findings prior to the procedure.
The clinical characteristics of each patient, such as their
age, gender, endoscopically measured tumor size, location
(location 1: upper, middle, and lower; location 2: greater
curvature, lesser curvature, anterior wall, and posterior
wall), and gross type (I: polypoid, IIa: elevated, IIb: flat,
IIc: depressed, others: mixed or unclassified), were evalu-
ated. For ESD, narrow-band imaging and endoscopic
ultrasound were routinely used. The number of biopsies
was usually 8 (4 inside and 4 outside the lesion), but the
number selected was ultimately left at the discretion of the
endoscopist rather than being strictly regulated. The tumor
invasion depth was judged by the endoscopist based on
their experience. Endoscopic findings suggestive of sub-
mucosal invasion [500 lm were an irregular mucosal
surface, marked marginal elevation, abrupt marginal cut-
ting, and substantial clubbing and fusion of converging
folds.
Pathological diagnosis
ESD specimens were fixed immediately on a plate using
pins, placed in 10 % neutral formalin for [4 h, and then
cut into 2-mm-thick slices and embedded completely in
paraffin. Hematoxylin and eosin (H&E) staining was per-
formed according to standard protocol and observed using
an optical microscope. For the pathological diagnosis, a
team of 16 pathologists experienced in gastrointestinal
pathology was organized and met 15 times for consensus
meetings. At least ten of the 16 team members attended
each meeting and examined the slides using a multiview
microscope; diagnoses were made via consensus. The
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diagnostic criteria for carcinoma were based on invasion,
per Western standards. If more than 6 of the 10 team
members present at the meeting agreed with a proposed
diagnosis, that diagnosis was considered final. In situations
where fewer than seven members agreed on a diagnosis, a
re-examination was conducted after a certain time interval
and voting was then performed again. In cases in which
less than seven of the members agreed on the diagnosis on
at least two occasions, the diagnosis that was most popular
among the members was considered the final diagnosis. In
this study, a total of 737 ESD specimens collected from
712 patients were used, and the final diagnosis of carci-
noma was made via the aforementioned process. Tissue
type, degree of differentiation, and depth of invasion were
also determined by voting and were assigned by the team
members in a similar manner.
Tissue type was classified as papillary, well differenti-
ated, moderately differentiated, poorly differentiated, or
other. The papillary and tubulopapillary adenocarcinomas
and the well and moderately differentiated adenocarcino-
mas were considered to be of ‘‘differentiated type.’’ Poorly
differentiated adenocarcinomas and signet ring cell carci-
nomas were considered to be of ‘‘undifferentiated type’’ by
voting. Cases (one each) of clear-cell carcinoma, carci-
noma with lymphoid stroma, and neuroendocrine carci-
noma were excluded. The degree of differentiation was
determined based on the extent of gland formation in the
entire tumor. Specifically, the degree of differentiation was
considered ‘‘well’’ if the extent of gland formation excee-
ded 95 %, ‘‘moderate’’ if the extent of gland formation was
50–95 %, and ‘‘poorly differentiated’’ if the extent of gland
formation was 0–49 %. The DOI was determined by the
deepest invasion of the tumor. Muscularis mucosae (MM)
infiltration was based on the clear invasion of the tumor
into the muscularis mucosae layer, rather than reactive
proliferation. The depth of submucosal invasion was
measured as the depth of tumor infiltration from directly
under the MM. The depth of submucosal invasion was
classified as SM1 (B500 lm) or SM2 ([500 lm). Ulcer-
ation was defined as MM exposure due to loss of gastric
mucosa. Cases in which the mucosa was reproduced post
ulcer and was subsequently covered with epithelial cells or
granulation tissue were not considered to present ulcera-
tion—only an active ulcer was considered a pathologic
ulcer. LVI was determined based on close visual exami-
nation by pathologists from each organization. D2-40 or
CD34 was conducted if diagnosis proved difficult based on
ordinary H&E staining. Venous invasion (VI), neural
invasion (NI), and the resection margin (RM) were also
judged by the pathologists in each organization. Statistical
analyses included Fisher’s exact test, the chi-square test,
and Bland–Altman plots.
Results
A total of 737 lesions were finally categorized as carci-
noma. The clinicopathologic characteristics of these lesions
are summarized in Table 1. These lesions were present in
712 patients (548 men and 164 women) ranging between
27 and 87 years of age (mean age: 62.8 years). ESD was
performed in cases of differentiated EGC without ulcera-
tion, lesion B3 cm in size, and submucosal invasion
B500 lm, but 20.1 % (148 cases) of the carcinoma cases
did not meet the inclusion criteria on the final pathological
evaluation, and 18 cases had two coincidental factors that
did not comply with the inclusion criteria. More specifi-
cally, 63 cases (8.5 %) had lesions[3 cm in size, 34 cases
(4.6 %) had ulceration, and 18 cases (2.4 %) were of the
undifferentiated type. In terms of invasion depth, there
were 368 cases (49.9 %) with invasion of lamina propria
(LP), 250 (33.9 %) with invasion of the MM, and 116
(15.7 %) with invasion of the submucosa (SM). Among the
cases with invasion of the SM, SM1 invasion B500 lm
was found in 65 cases (8.8 %) and SM2 invasion[500 lm
in 51 cases (6.9 %). The DOI could not be determined in
three cases (0.4 %) because there was involvement of the
deep RM by the deepest focus of the tumor. Lateral and
deep RM involvement was observed in three and 13 cases,
respectively. LVI was observed in 31 cases (4.2 %).
Results for gross type and location are also summarized in
Table 1. The most common type was IIc. There were no
cases of gross type III (excavated) because the cases with
ulceration were excluded. The lower third and the lesser
curvature were most common for locations 1 and 2.
Comparison of endoscopic and pathological tumor
sizes
Endoscopic tumor size data were available in 707 cases
(Tables 2, 3; Fig. 1). A comparison of the mean endo-
scopic and pathological tumor sizes is presented in Table 2.
Figure 1 shows the associated scatter and Bland–Altman
plots. The absolute difference between the average endo-
scopic and pathological measurements was proportional to
tumor size. The mean endoscopic measurement was sig-
nificantly lower than the mean pathological estimate
(1.51 ± 0.66 cm vs. 1.66 ± 1.02 cm, p\ 0.001). An
absolute difference of B0.5 cm was found in 55.0 % (389/
707) of cases. The Bland–Altman plot showed that 93.2 %
of cases were within the 95 % limits of agreement. The
tumor size had a statistically significant correlation with
DOI (p = 0.028), gross type, and location 1, but did not
have any correlation with ulcer, degree of differentiation,
LVI, or location 2 (p[ 0.05) (Table 3). In an additional v2
test, cases showing SM invasion, elevated gross
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morphology (EGC type I vs. IIb or IIc, and IIa vs. IIc), and
upper or middle location were associated with tumor size
[3 cm (p\ 0.05). In particular, the proportion of the cases
with lesion size[3 cm decreased with type: type I (44.4 %)
[ IIa (17.7 %) [ IIb (9.9 %) [ IIc (7.3 %). The largest
pathologic tumor was 8.5 cm in size; in this case, the
endoscopic tumor size was 2 cm and it was located at the
greater curvature of the cardia. Pathologically, the tumor
was tubular, well differentiated, and confined to the
muscularis mucosae, without ulceration or LVI. Even
though there was such a large discrepency between the
pathological and endoscopic tumor sizes, the resection
margin in this case was free of tumor.
Comparison of endoscopic and pathological ulcers
In 34 cases (4.6 %) with pathological (active) ulcers, the
DOI was statistically significantly deeper than in cases
Table 1 Clinicopathologic
characteristics of the 737
endoscopic submucosal
dissection cases that were
finally diagnosed as carcinoma
Clinicopathologic finding Classification Number of specimens (%)
Gender Male 564 (76.5)
Female 173 (23.5)
Age (years) \50 59 (8.0)
50–59 224 (30.4)
60–69 283 (38.4)
C70 171 (23.2)
Size B3 cm 674 (91.5)
[3 cm 63 (8.5)
Ulcer Absent 703 (95.4)
Present 34 (4.6)
Differentiation Differentiated 719 (97.6)
Undifferentiated 18 (2.4)
Depth of invasion Mucosal cancer
Lamina propria 368 (49.9)
Muscularis mucosae 250 (33.9)
Submucosal cancer
Submucosal invasion B500 lm 65 (8.8)
Submucosal invasion[500 lm 51 (6.9)
Uncertain 3 (0.4)
Resection margin involvement
Lateral Absent 734 (99.6)
Present 3 (0.4)
Deep Absent 724 (98.2)
Present 13 (1.8)
Gross type EGC I 9 (1.2)
EGC IIa 79 (10.7)
EGC IIb 111 (15.1)
EGC IIc 332 (45.1)
Others 7 (0.9)
No data 199 (27.0)
Location 1 Upper 85 (11.5)
Middle 187 (25.4)
Lower 465 (63.1)
Location 2 Anterior wall 148 (20.1)
Lesser curvature 282 (38.3)
Posterior wall 140 (19.0)
Greater curvature 167 (22.7)
Lymphovascular invasion Absent 706 (95.8)
Present 31 (4.2)
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Table 2 Comparison of endoscopic and pathological tumor sizes
Endoscopic tumor size (E) Pathological tumor size (P)
Mean ± SD (cm) 1.51 ± 0.66 1.66 ± 1.02
Range (cm) 0.1–3.0 0.1–8.5
Number (%) of cases: E\P 325 (46.0 %)
Number (%) of cases: E = P 81 (11.4 %)
Number (%) of cases: E[P 301 (42.6 %)
Limits of agreement (reference range for difference) -1.74 to 2.04
Mean difference 0.148 (CI 0.077–0.219)
Table 3 Clinicopathologic
analysis according to tumor size
Clinicopathologic factor Pathological tumor size [number of cases (%)/relative %] p value
B3 cm [3 cm
Ulcer 0.350
Absent 641 (87.0)/95.1 (641/674) 62 (8.4)/98.4 (62/63)
Present 33 (4.5)/4.9 (33/674) 1 (0.1)/1.6 ( 1/63)
Differentiation 0.194
Differentiated 657 (89.4)/97.8 (657/672) 60 (8.1)/95.2 (60/63)
Undifferentiated 15 (2.0)/2.2 (15/672) 3 (0.4)/4.8 (3/63)
Depth of invasion 0.028
Lamina propria 344 (46.9)/51.0 (344/674) 24 (3.3)/38.1 (24/63)
Muscularis mucosae 229 (31.2)/34.0 (229/674) 21 (2.9)/33.3 (21/63)
SM1 55 (7.5)/8.2 (55/674) 10 (1.4)/15.9 (10/63)
SM2 43 (5.9)/6.4 (43/674) 8 (1.1)/12.7 (8/63)
Uncertain 3 (0.4)/0.4 (3/674)
Lymphovascular invasion 0.175
Absent 648 (87.9)/96.1 (648/674) 58 (7.9)/92.1 (58/63)
Present 26 (3.5)/3.9 (26/674) 5 (0.7)/7.9 (5/63)
Gross type \0.001
EGC I 5 (0.9)/1.0 (5/492) 4 (0.7)/8.7 (4/46)
EGC IIa 65 (12.1)/13.2 (65/492) 14 (2.6)/30.4 (14/46)
EGC IIb 100 (18.6)/20.3 (100/492) 11 (2.0)/23.9 (11/46)
EGC IIc 315 (58.6)/64.0 (315/492) 17 (3.2)/37.0 (17/46)
Others 7 (1.3)/1.4 (7/492) 0 (0.0)/0.0 (0/46)
Location 1 0.004a
Upper 72 (9.8)/10.7 (72/674) 13 (1.8)/20.6 (13/63)
Middle 165 (22.4)/24.5 (165/674) 22 (3.0)/34.9 (22/63)
Lower 437 (59.3)/64.8 (437/674) 28 (3.8)/44.4 (28/63)
Location 2 0.944a
Anterior wall 135 (18.3)/20.0 (135/674) 13 (1.8)/20.6 (13/63)
Lesser curvature 256 (34.7)/38.0 (256/674) 26 (3.5)/41.3 (26/63)
Posterior wall 129 (17.5)/19.1 (129/674) 11 (1.5)/17.5 (11/63)
Greater curvature 154 (20.9)/22.8 (154/674) 13 (1.8)/20.6 (13/63)
Total 674 (91.5) 63 (8.5)
a Chi-square test
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without ulcers (p = 0.005). In cases showing SM invasion,
ulceration was more frequent (p = 0.003). The presence or
absence of a pathological ulcer was not correlated statis-
tically with tumor size, degree of differentiation, LVI,
gross type, or location (p[ 0.05). Just one case in the
group with lesions [3 cm showed ulceration. Thus, in
cases with a large tumor, the endoscopist tended to be
stringent when checking for ulceration.
Discrepancy in differentiation pre- and post-ESD
Among the ESD specimens, 18 cases (2.4 %) were cate-
gorized as undifferentiated, and the diagnosis for 97.6 % of
those patients was consistent with the biopsy diagnosis for
tumor differentiation. Unusual histologic types of cancer
were excluded from the analysis. Among the undifferen-
tiated cases, submucosal invasion was found in eight cases
(44.4 %) and LVI in four cases (22.2 %). On univariate
analysis, DOI and LVI were correlated with differentiation
(p = 0.021, p = 0.007, respectively). In an additional v2
test, undifferentiated histology was associated with SM
invasion (SM1 or SM2) (p = 0.01). However, no statistical
correlation with tumor size, ulceration, gross type, or
location was found.
Discrepancy in DOI pre-and post-ESD
Patients who underwent ESD were assumed to have
mucosal or SM1 cancer on preoperative evaluation. How-
ever, an invasion depth of SM2 or more was found in 51
cases (6.9 %; see Table 4), representing approximately half
(44.0 %) of all cases with submucosa invasion. On multi-
variate analysis, DOI showed correlations with tumor size,
ulceration, differentiation, LVI, gross type, and locations 1
and 2. These results imply that such pathological factors
are important for predicting pathological T staging. In an
additional v2 test and Fisher’s exact test, the mucosal
cancer group (LP and MM invasion) showed statistically
significant differences in tumor size, differentiation,
ulceration, LVI, location 1, and location 2 compared to the
SM cancer group (SM1 and SM2 invasion). In contrast,
cancers associated with the superficial invasion group (LP,
MM, and SM1 invasion) showed no significant differences
in tumor size, differentiation, and ulceration compared to
the deep invasion group (SM2 invasion). Based on these
results, excluding SM-invasive cancer would be expected
to reduce the rate of discrepancy between the clinico-
pathologic parameters before and after ESD. However, the
risk of LVI differed statistically significantly between
groups no matter which of the groups were compared.
Discussion
ESD should only be assigned based on strict criteria in
order to avoid lymph node (LN) metastasis. Gotoda et al.
[3] reported that LN metastasis was not observed in any
case of ulcer-free differentiated mucosal cancer, regardless
of the tumor size. However, Kang et al. [4] reported LN
metastasis in two (1.4 %) of 146 cases of intestinal-type
mucosal cancer of any size without ulcer and with no
lymphovascular emboli. Chung et al. [5] also reported LN
metastasis in two (0.23 %) of 882 patients with ulcer-free
differentiated mucosal cancer regardless of the tumor size.
In a study involving 487 EGC cases treated with ESD, Lee
et al. [6] suggested that ESD for curative purposes was
most feasible in nonulcerative cases and that differentiated
EGC was the best option for tumors B cm in size. Thus, in
Fig. 1 Scatterplot (left) and Bland–Altman plot (right) of the endoscopic and pathological tumor sizes
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the present study, cases with ulcers and tumors[3 cm in
size were excluded to decrease the risk of metastasis that
could result from the application of the extended criteria.
The definition of gastric carcinoma can vary among
pathologists. Japanese pathologists base a diagnosis of
cancer on severe cytologic atypia with enlarged vesicular
oval nuclei and prominent nucleoli, irrespective of the
presence of invasion. On the other hand, Western pathol-
ogists believe that evidence of invasion into the LP must be
present to make a cancer diagnosis. However, apparent
invasion is not easily observed in well-differentiated car-
cinomas. Therefore, very careful and close microscopic
examination is required, along with a pathologist with
extensive experience. Histologic findings of high-grade
dysplasia/adenoma overlap with those of well-differenti-
ated adenocarcinoma, even if the diagnosis is based on the
same criteria, so the diagnosis may differ depending on the
pathologist [7, 8]. In this study, the Western viewpoint was
applied, and a multicenter study was conducted to mini-
mize evaluation errors arising from differences in diag-
nostic criteria. Obtaining a diagnostic consensus among 10
pathologists allowed cases of high-grade dysplasia to be
excluded. Moreover, a set of criteria were defined,
including those for measuring the depth of invasion, to
evaluate the degree of differentiation and pathological
findings of ulceration.
Discrepancies between endoscopic and pathological
tumor sizes result not only from differences in the mea-
surement methods used, such as visual estimations, open
biopsy forceps, and linear probes [9], but also from vari-
ations in practitioner experience [10]. In addition, tumor
location, endoscopic approach to the lesion, and gross and
histologic type may affect the accuracy. Choi et al. [10]
reported reliable agreement between endoscopic visual
Table 4 Clinicopathologic
analysis according to the depth
of invasion
Clinicopathologic factor DOI [number of cases (%)] p value
LP MM SM1 SM2 Total
Tumor size 0.028
B3 cm 344 (46.9) 229 (31.2) 55 (7.5) 43 (5.9) 671 (91.4)
[3 cm 24 (3.3) 21 (2.9) 10 (1.4) 8 (1.1) 63 (8.6)
Ulcer 0.005
Absent 357 (48.6) 239 (32.6) 56 (7.6) 48 (6.5) 700 (95.4)
Present 11 (1.5) 11 (1.5) 9 (1.2) 3 (0.4) 34 (4.6)
Differentiation 0.021
Differentiated 363 (49.5) 245 (33.4) 60 (8.2) 49 (6.7) 717 (97.7)
Undifferentiated 5 (0.7) 5 (0.7) 5 (0.7) 2 (0.3) 17 (2.3)
LVI \0.001
Absent 367 (50.0) 245 (33.4) 52 (7.1) 37 (5.0) 701 (95.5)
Present 1 (0.1) 5 (0.7) 13 (1.8) 14 (1.9) 33 (4.5)
Gross type \0.001
EGC I 1 (0.2) 6 (1.1) 0 (0.0) 2 (0.4) 9 (1.7)
EGC IIa 49 (9.1) 16 (3.0) 2 (0.4) 12 (2.2) 79 (14.7)
EGC IIb 61 (11.4) 35 (6.5) 12 (2.2) 2 (0.2) 110 (20.5)
EGC IIc 152 (28.4) 124 (23.1) 34 (6.3) 21 (3.9) 331 (61.8)
Others 4 (0.7) 2 (0.4) 0 (0.0) 1 (0.2) 7 (1.3)
Location 1 0.008a
Upper 35 (4.8) 23 (3.1) 15 (2.0) 11 (1.5) 84 (11.4)
Middle 95 (12.9) 65 (8.9) 16 (2.2) 9 (1.2) 185 (25.2)
Lower 238 (32.4) 162 (22.1) 34 (4.6) 31 (4.2) 465 (63.4)
Loccation 2 0.022a
Anterior wall 79 (10.8) 41 (5.6) 16 (2.2) 12 (1.6) 148 (20.2)
Lesser curvature 142 (19.3) 101 (13.8) 26 (3.5) 11 (1.5) 280 (38.1)
Posterior wall 57 (7.8) 51 (6.9) 15 (2.0) 17 (2.3) 140 (19.1)
Greater curvature 90 (12.3) 57 (7.8) 8 (1.1) 11 (1.5) 166 (22.6)
Total 368 (50.1) 250 (34.1) 65 (8.9) 51 (6.9)
Fisher’s exact test
a Chi-square test
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estimation and pathological measurement as well as good
interobserver agreement. In our study, 6.8 % of the cases
were outside of the 95 % limits of agreement, and such
deviations occurred more frequently in cases with larger
lesions. The largest discrepancy between endoscopic and
pathological tumor size was 6.5 cm. The reason for this
large discrepancy was not clear. Based on the free ESD
margin in this particular case, the endoscopist may have
defined the tumor border as the only discrete area, not
including the suspicious portion. According to our study,
tumor location in the upper or mid portion and elevated
gross morphology were causes of endoscopic size under-
estimation leading to categorization as \3 cm, but histo-
logic type of tumor was not. In the literature, Asada-
Hirayama et al. [11] reported that presence of a flat com-
ponent, large size, and moderately differentiated histology
were significantly related to inaccurate endoscopic evalu-
ation in intestinal-type early gastric cancer. However, their
results were not comparable with those from our study
because their study focused on whether pretreatment
demarcation was accurate or not. In the study of Shim et al.
[12], larger size, flat/depressed type, and undifferentiated
histology were independent risk factors for endoscopic size
underestimation, and smaller size was the only independent
predictor for endoscopic overestimation of size. An abso-
lute difference of less than 0.4 cm was found in 47.1 % of
cases in their study, similar to the corresponding value
obtained in our study (an absolute difference of B0.5 cm in
55.0 % of cases). According to the current study, elevated
gross type was commonly found in cases[3 cm, probably
due to somewhat excessive enrollment of patients pre-
senting a discrete elevated gross morphology. DOI was
meaningfully deep in the cases with lesions [3 cm
(p = 0.028); thus, tumor depth should be estimated cau-
tiously in these cases.
An ulcer is a discontinuity of the mucosal layer caused
by loss of this layer. The presence or absence of ulceration
influences LN metastasis in EGC. The study by Gotoda
et al. [3] showed that the incidence of LN metastasis was
3.4 % for mucosal cancer with ulceration and 0.5 % for
mucosal cancer without ulceration. According to the meta-
analysis of EGC by Kwee et al. [13], there was a high risk
of LN metastasis when an ulcer was present, although more
than moderate heterogeneity was apparent in the studies
investigating this variable. They suggested that the reason
for this heterogeneity was interobserver variability in the
assessment of tumor ulceration among studies. In the study
by Gotoda et al. [3], they defined an ulcer as a lesion with
ulceration or scarring from previous ulceration. Nonethe-
less, accurately distinguishing between an ulcer and ero-
sion by endoscopy is a difficult task because such erosion
also involves damage to the mucosal layer. Lee et al. [14]
emphasized that the morphology of an ulcer may change
over time, considering the life cycle of a malignant ulcer,
and that interobserver variation may result when the pres-
ence or absence of ulcer is determined endoscopically. In
the present study, the main focus was the discrepancy
between clinicopathologic variables pre- and post-ESD.
Thus, we compared the pre-ESD endoscopic ulceration
with the post-ESD pathologic ulceration. We considered it
reasonable to define a pathologic ulcer as an active ulcer
with no scarring from ulceration. We also excluded lesions
that were regenerating post ulcer and were covered with
epithelial cells or granulation tissue. Despite the applica-
tion of strict pathological criteria, accurate endoscopic
evaluation of ulcers proved difficult considering that 34
cases (4.6 %) with ulceration were included. However,
there was only one case with both ulceration and a dif-
ferentiated mucosal carcinoma[3 cm in size, which con-
stitutes deviation from the extended criteria, implying that
the endoscopists strictly applied the criteria for distin-
guishing the presence or absence of an ulcer when the
tumor was large. In this study, the DOI was significantly
deeper in cases with ulceration than in those without
ulceration. Therefore, accurate endoscopic determination
of the presence or absence of ulceration may be necessary.
The degree of differentiation is a very important factor
in candidate selection. In the WHO classification [15],
tumor differentiation is determined by the grading of gland
formation. According to the Japanese Gastric Cancer
Association [16], undifferentiated gastric carcinomas
include poorly differentiated adenocarcinomas and signet
ring cell carcinomas, while differentiated carcinomas
include well and moderately differentiated tubular carci-
nomas. Interobserver variability is even present when
defining differentiation. In this study, the degree of dif-
ferentiation was determined by a consensus meeting to
eliminate this interobserver variability. In cases of undif-
ferentiated intramucosal EGC, curative endoscopic treat-
ment can be conducted only in very limited cases because
it has a higher frequency of LN metastasis than intramu-
cosal EGC does (4.2 vs. 0.4 %) [3]. According to the meta-
analysis conducted by Kwee [13], more than moderate
heterogeneity was identified among studies investigating
the variable ‘‘main histological tumor type (differentiated
vs. undifferentiated).’’ Pre-ESD biopsy of the tumor
sometimes results in a different histology to that seen in the
post-ESD specimen, which can be attributed to inter- and
intraobserver variability as well as the fact that a gastric
cancer can present histological heterogeneity (it can be
both differentiated and undifferentiated) [17, 18]. Mita and
Shimoda [19] reported that the rate of LN metastasis was
significantly higher in differentiated submucosal cancers
with histological heterogeneity (i.e., of differentiated type
with a poorly differentiated component) than in cancers
without such histological heterogeneity (27 vs. 7 %). Lee
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et al. [20] compared the histologic differentiation observed
using radical gastrectomy with that seen in preoperative
gastric biopsy in 1326 patients with gastric mucosal cancer.
The results showed that the degree of differentiation was
consistent in 1041 patients (78.5 %); 99 patients (7.5 %)
showed a differentiated histology on preoperative biopsy
but a poorly differentiated histology on postoperative
results, whereas the opposite was seen in 58 patients
(4.4 %). Matsubara et al. [21] compared the pre- and
postoperative differentiation of gastric cancer. The rates of
agreement for early and advanced gastric cancer were 82.5
and 72 %, respectively. In the differentiated cases, the rates
of agreement were 90.0 and 63.6 % for early and advanced
cancers, respectively. Our study targeted cases diagnosed
as differentiated on biopsy; among those cases, only 19
were found to be the undifferentiated type, with a consis-
tency rate as high as 97.4 %. Our high consistency rate can
be attributed to the application of the strict inclusion cri-
teria applied to ESD, whereas the studies by Lee et al. [20]
and Matsubara et al. [21] targeted patients who underwent
gastrectomy. Additionally, in our study, the undifferenti-
ated group showed deeper invasion and more frequent LVI
than the differentiated group did. This result indicates that
tumor heterogeneity is commonly associated with deep
invasion and LVI.
Accurate diagnosis of invasion depth prior to the ESD
procedure is very important when attempting to identify
an appropriate treatment plan. DOI can be determined by
conventional endoscopy, a barium study, endoscopic
ultrasonography (EUS), virtual endoscopy, or abdominal
CT [22]. Mandai et al. [23] measured the invasion depth
of EGC using EUS. Among the 280 cases considered to
be mucosal/SM1 cancer based on EUS findings, 20
(7.1 %) corresponded to SM2 cancer. This result was
similar to our finding of 51 such cases (6.9 %). Mandai
et al. [23] stated that the factors leading to misdiagnosis
based on DOI measurement include ulceration, tumor size
[2 cm, and use of an US endoscope. Yamada et al. [24]
described three risk factors for submucosal and lympho-
vascular invasion in ESD specimens: a dominant histol-
ogy of moderately differentiated or papillary
adenocarcinoma; a non-flat-type gross morphology; and a
tumor size C1.5 cm. In our study, SM2 invasion corre-
lated with tumor size, ulceration, undifferentiated histol-
ogy, gross type, and location of the tumor in the
multivariate analysis. Among the 117 cases showing
submucosal invasion, 52 (44.4 %) demonstrated SM2
invasion. Therefore, in cases suspicious for submucosal
invasion, very careful selection of the patients for ESD is
mandatory in order to prevent the need for additional
surgery. According to the extended criteria for ESD eli-
gibility, SM1 cancer is eligible for ESD, but the mucosal
cancer group (LP and MM invasion) showed statistically
significant differences in tumor size, differentiation,
ulceration, LVI, location 1, and location 2 compared to
the SM cancer group (SM1 and SM2 invasion) in our
study. In contrast, cancers associated with the superficial
invasion group (LP, MM, and SM1 invasion) revealed no
significant differences in tumor size, differentiation, and
ulceration compared to the deep invasion group (SM2
invasion). Based on these results, excluding SM-invasive
cancer would be expected to reduce the rate of discrep-
ancy between the clinicopathologic parameters before and
after ESD. However, in our study, the risk of LVI differed
statistically significantly between groups regardless of the
groups compared.
Conclusions
Among 737 cases of carcinoma in EGC patients, discrep-
ancies in the clinicopathologic parameters pre- and post-
ESD occurred in 148 (20.1 %). The most common cause of
discrepancy was tumor size[3 cm (63 cases, 8.5 %), but
93.2 % of these cases lay within the 95 % limits of agree-
ment. Ulceration, undifferentiated histology, and SM2
invasion were found in 34 cases (4.6 %), 18 cases (2.4 %),
and 51 cases (6.9 %), respectively. Depth of invasion was
correlated with other clinicopathologic parameters such as
tumor size, ulceration, differentiation, and LVI. DOI should
therefore be evaluated very cautiously in order to reduce the
discrepancy rate. Among the 116 cases that showed sub-
mucosal invasion, 51 cases (44.0 %) demonstrated SM2
invasion. SM-invasive cancer cases showed a high incidence
of LVI irrespective of the depth of SM invasion. In cases
suspicious for submucosal invasion, cautious selection of
patients for ESD is necessary in order to reduce the risk of
SM2 invasion and LVI.
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